Updated:
Indaptus Therapeutics, Inc.
Indaptus Therapeutics was founded to commercialize a platform technology discovered by scientists at the National Cancer Institute. The company's approach uses...
Indaptus Therapeutics, Inc.
Indaptus Therapeutics was founded to commercialize a platform technology discovered by scientists at the National Cancer Institute. The company's approach uses a bacterial vector to stimulate a broad immune response, aiming to improve outcomes in oncology and virology. Indaptus is headquartered in New York City and operates as a publicly traded company, with its common stock listed on the Nasdaq Capital Market. Indaptus's pipeline centers on Decoy20, a bacteriophage-derived immunotherapy product. The company is evaluating Decoy20 in a Phase 1/2 clinical trial for advanced solid tumors, with early data reported in 2024. Indaptus also explores applications in hepatitis B and other infectious diseases. The firm collaborates with academic institutions for preclinical studies, including the National Cancer Institute (per SEC filings, 2024). As of 2024, Indaptus employs approximately 10 professionals, including a small management team led by CEO Jaffrey Adam Feuerstein. The company has no revenue from product sales and operates at a net loss, funding operations through equity offerings and collaborations. In November 2024, Indaptus entered into a securities purchase agreement with a single institutional investor for a $3.75M private placement (per SEC filing, November 2024). The company maintains no known adjacent philanthropic or operating vehicles. A structural differentiator is Indaptus's platform technology, which is designed to address a fundamental limitation of existing immunotherapies: lack of broad innate immune activation. The Decoy20 platform is based on a synthetic biology approach that avoids the toxicity of live bacterial therapies while preserving immunological potency. This distinguishes Indaptus from other immuno-oncology firms that focus primarily on adaptive immune checkpoints or CAR-T cells.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who runs investment decisions at Indaptus Therapeutics?
Indaptus Therapeutics is a publicly traded biotechnology company, so investment decisions are made by its board of directors and executive management, including CEO Jeffrey Feuerstein. The board oversees major strategic and financial decisions, while day-to-day operations are managed by the executive team (per SEC filings, 2024).
How does Indaptus source proprietary deal flow?
Indaptus does not operate as an investment firm; it is a clinical-stage biotechnology company. Its pipeline is internally developed based on a platform technology licensed from the National Cancer Institute (per SEC filings, 2024). The company may explore in-licensing or collaborations, but its primary focus is advancing its own assets.
Is Indaptus structured as a single family office or does it operate more like a venture firm?
Indaptus Therapeutics is neither a family office nor a venture firm. It is a publicly traded biotechnology corporation (Nasdaq: INDP) with a market capitalization of roughly $10-15 million as of mid-2025 (per public market data). Its structure is a typical biotech issuer with a board and executive team.
Does Indaptus participate in fund commitments or only direct deals?
Indaptus does not make fund commitments or direct investments. It is an operating company that raises capital from investors, not an allocator of capital. Its funding comes from equity offerings, including recent registered direct offerings (per SEC filings, 2024).
What investment stages does Indaptus typically target?
Indaptus does not target investment stages as it is not an investment firm. It operates as a clinical-stage biotech company, with its lead candidate in Phase 1/2 trials for advanced solid tumors (per SEC filings, 2024). The company is pre-revenue and pre-commercial.
Which sectors does Indaptus explicitly avoid?
Indaptus focuses exclusively on biotechnology and healthcare, specifically immunotherapy for oncology and infectious diseases. It has no disclosed exposure to other sectors like technology, real estate, or financial services (per the firm's public filings, 2024).
Does Indaptus maintain philanthropic structures, and how are they separated?
Indaptus Therapeutics does not appear to operate any philanthropic structures. As a publicly traded company, it is subject to disclosure requirements, and no foundation or charitable arm is mentioned in its SEC filings or public communications (per SEC filings, 2024).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: